NEW YORK (GenomeWeb) – Tianjin Novogene Bioinformatics Technology announced today that the China Food and Drug Administration has approved the firm's NovoFocus NSCLC CDx assay.

The next-generation sequencing-based diagnostic test simultaneously analyzes tumor samples for multiple genomic mutations that are targeted by several CDFA-approved therapies for non-small cell lung cancer, including Iressa (gefitinib), Tagrisso (osimertinib), and Xalkori (crizotinib).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.

An opinion piece at Bloomberg discusses China's stance on genomic research.

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.